

**UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME FOR THE FOURTH QUARTER ENDED 31 DECEMBER 2021**

	Note	Individual quarter		Cumulative quarter	
		Current year quarter	Preceding year quarter	Current year-to-date	Preceding year-to-date
		31/12/2021 RM'000	31/12/2020 RM'000	31/12/2021 RM'000	31/12/2020 RM'000
<b>Revenue</b>		49,096	42,005	169,505	146,683
Cost of sales		(34,755)	(30,813)	(118,327)	(105,655)
<b>Gross profit</b>		14,341	11,192	51,178	41,028
Other operating income		624	992	1,798	1,464
Distribution costs		(498)	(1,445)	(9,881)	(8,770)
Administration expenses		(8,623)	(5,950)	(24,212)	(20,803)
Finance costs		(253)	(297)	(1,278)	(1,382)
<b>Profit before tax</b>		5,591	4,492	17,605	11,537
Tax expense	B5	(2,079)	(1,221)	(5,086)	(3,171)
<b>Profit for the financial period</b>		3,512	3,271	12,519	8,366
Other comprehensive income, net of tax		-	-	-	-
<b>Total comprehensive income</b>		3,512	3,271	12,519	8,366
<b>Profit attributable to:</b>					
Owners of the parent		3,137	2,634	11,268	7,285
Non-controlling interests		375	637	1,251	1,081
		3,512	3,271	12,519	8,366
<b>Total comprehensive income attributable to:</b>					
Owners of the parent		3,137	2,634	11,268	7,285
Non-controlling interests		375	637	1,251	1,081
		3,512	3,271	12,519	8,366
<b>Earnings per ordinary share attributable to owners of the parent:</b>					
- Basic (sen)	B14	1.56	1.31	5.61	3.73
- Diluted (sen)	B14	1.12	1.31	4.01	3.73

The Unaudited Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income should be read in conjunction with the audited financial statements for the financial year ended 31 December 2020 and the accompanying explanatory notes attached to these interim financial statements.

**UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION AS AT 31 DECEMBER 2021**

	Note	As at 31/12/2021 RM'000	Audited As at 31/12/2020 RM'000
<b>Non-current asset</b>			
Property, plant and equipment		78,523	73,127
Right-of-use assets		11,142	12,605
Investment property		5,567	5,610
Biological assets		3,367	2,217
Goodwill		3,941	3,941
Other investment	B8	24	31
		<u>102,564</u>	<u>97,531</u>
<b>Current assets</b>			
Inventories		33,246	30,631
Trade and other receivables		38,578	33,171
Current tax assets		799	185
Cash and bank balances and short term funds		18,112	24,476
		<u>90,735</u>	<u>88,463</u>
<b>Total assets</b>		<u>193,299</u>	<u>185,994</u>
<b>Equity</b>			
Share capital		103,618	103,618
Reorganisation debit balance	B16	(59,489)	(59,489)
Retained earnings		87,236	79,985
<b>Total attributable to owners of the parent</b>		<u>131,365</u>	<u>124,114</u>
Non-controlling interests		7,788	6,537
<b>Total equity</b>		<u>139,153</u>	<u>130,651</u>
<b>Non-current liabilities</b>			
Borrowings	B9	25,698	30,429
Lease liabilities		177	492
Deferred tax liabilities		1,918	435
		<u>27,793</u>	<u>31,356</u>
<b>Current Liabilities</b>			
Trade and other payables		20,250	18,076
Borrowings	B9	4,579	4,369
Lease liabilities		315	337
Current tax liabilities		1,209	1,205
		<u>26,353</u>	<u>23,987</u>
<b>Total liabilities</b>		<u>54,146</u>	<u>55,343</u>
<b>Total equity and liabilities</b>		<u>193,299</u>	<u>185,994</u>
<b>Net assets per share attributable to owners of the parent (RM)</b>	B15	0.65	0.62

The Unaudited Condensed Consolidated Statement of Financial Position should be read in conjunction with the audited financial statements for the financial year ended 31 December 2020 and the accompanying explanatory notes attached to these interim financial statements.

**UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY FOR THE FOURTH QUARTER ENDED 31 DECEMBER 2021**

	<----- Attributable to owners of the parent ----->		<----- Non-distributable ----->		Distributable	Total attributable to owners of the parent	Non-controlling interest	Total equity
	Share capital	Reorganisation debit balance	Retained earnings	Total attributable to owners of the parent				
	RM'000	RM'000	RM'000	RM'000	RM'000	RM'000	RM'000	RM'000
<b>Balance as at 1 January 2021</b>	103,618	(59,489)	79,985	124,114	6,537	130,651		
Profit for the financial year	-	-	11,268	11,268	1,251	12,519		
Other comprehensive income, net of tax	-	-	-	-	-	-		
Total comprehensive income	-	-	11,268	11,268	1,251	12,519		
Transactions with owners:								
Dividends paid	-	-	(4,017)	(4,017)	-	(4,017)		
Total transactions with owners	-	-	(4,017)	(4,017)	-	(4,017)		
<b>Balance as at 31 December 2021</b>	103,618	(59,489)	87,236	131,365	7,788	139,153		
<b>Balance as at 1 January 2020</b>	92,114	(59,489)	74,709	107,334	-	107,334		
Profit for the financial year	-	-	7,285	7,285	1,081	8,366		
Other comprehensive income, net of tax	-	-	-	-	-	-		
Total comprehensive income	-	-	7,285	7,285	1,081	8,366		
Transactions with owners:								
Issuance of ordinary shares	11,504	-	-	11,504	-	11,504		
Dividends paid	-	-	(2,009)	(2,009)	-	(2,009)		
Acquisition of subsidiaries	-	-	-	-	3,926	3,926		
Issuance of ordinary shares to non-controlling interest	-	-	-	-	1,530	1,530		
Total transactions with owners	11,504	-	(2,009)	9,495	5,456	14,951		
<b>Balance as at 31 December 2020</b>	103,618	(59,489)	79,985	124,114	6,537	130,651		

The Unaudited Condensed Consolidated Statement of Changes in Equity should be read in conjunction with the audited financial statements for the financial year ended 31 December 2020 and the accompanying explanatory notes attached to these interim financial statements.

**UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS FOR THE FOURTH QUARTER ENDED 31 DECEMBER 2021**

	<b>Current year- to-date 31/12/2021 RM'000</b>	<b>Preceding year-to-date 31/12/2020 RM'000</b>
<b>Cash flows from operating activities</b>		
Profit before tax	17,605	11,537
Adjustments for:		
Depreciation	3,607	2,166
Inventories written off	809	2,172
Inventories written down/(back)	590	(279)
Impairment losses/(write back) on trade receivables	258	(318)
Fair value changes on other investment	7	9
Interest expense	1,278	1,382
Loss on disposal of biological assets	161	-
Fair value changes on biological assets	(560)	(466)
Interest income	(175)	(177)
Gain on bargain purchase of a subsidiary	-	(138)
Unrealised (gain)/loss on foreign currency exchange	(413)	441
Operating profit before working capital changes	<u>23,167</u>	<u>16,329</u>
Changes in working capital:		
Inventories	(4,013)	2,844
Trade and other receivables	(5,666)	1,574
Trade and other payables	579	(965)
Cash generated from operations	<u>14,067</u>	<u>19,782</u>
Tax paid	<u>(4,213)</u>	<u>(2,840)</u>
Net cash from operating activities	<u>9,854</u>	<u>16,942</u>
<b>Cash flows from investing activities</b>		
Purchase of property, plant and equipment	(8,390)	(5,441)
Acquisition of subsidiaries, net of cash acquired	-	(1,329)
Issuance of ordinary shares to non-controlling interest	-	1,530
Interest received	175	177
Purchase of biological assets	(835)	-
Proceeds from disposal of biological assets	84	-
Proceed from disposal of right-of-use asset	1,026	-
Net cash used in investing activities	<u>(7,940)</u>	<u>(5,063)</u>
<b>Cash flows from financing activities</b>		
Net repayment of borrowings	(4,521)	(1,086)
Interest paid	(1,249)	(1,359)
Dividend paid	(2,009)	(2,009)
Payment of lease liabilities	(499)	(336)
Net proceeds from issuance of shares	-	8,178
Net cash (used in)/from financing activities	<u>(8,278)</u>	<u>3,388</u>
Net (decrease)/increase in cash and cash equivalents	(6,364)	15,267
Cash and cash equivalents at beginning of financial year	<u>24,476</u>	<u>9,209</u>
Cash and cash equivalents at end of financial year	<u>18,112</u>	<u>24,476</u>

The Unaudited Condensed Consolidated Statement of Cash Flows should be read in conjunction with the audited financial statements for the financial year ended 31 December 2020 and the accompanying explanatory notes attached to these interim financial statements.

**A. EXPLANATORY NOTES PURSUANT TO MALAYSIAN FINANCIAL REPORTING STANDARDS (“MFRS”) 134: INTERIM FINANCIAL REPORTING**

**A1. Basis of preparation**

The unaudited interim financial statements have been prepared in accordance with the requirements of MFRS 134 *Interim Financial Reporting* and paragraph 9.22 of the Main Market Listing Requirements of Bursa Malaysia Securities Berhad.

These explanatory notes attached to the interim financial statements provide an explanation of events and transactions that are significant to an understanding of the changes in the financial position and performance of the Group since the financial year ended 31 December 2020 and should be read in conjunction with the audited financial statements of the Group for the financial year ended 31 December 2020.

**A2. Significant accounting policies**

The significant accounting policies and methods of computation adopted for the interim financial statements are consistent with those adopted for the audited financial statements of the Group for the financial year ended 31 December 2020, except for the adoption of the following amendments to MFRSs during the financial year:

- *Interest Rate Benchmark Reform - Phase 2* (Amendments to MFRS 9, MFRS 139, MFRS 7, MFRS 4 and MFRS 16)
- *Covid-19-Related Rent Concessions beyond 30 June 2021* (Amendment to MFRS 16 *Leases*)

The adoption of the above amendments had no significant impact to the financial statements of the Group.

**A3. Auditors’ report**

There was no qualification to the audited financial statements of the Company and its subsidiaries for the financial year ended 31 December 2020.

**A4. Seasonal or cyclical factors**

The business operations of the Group were not materially affected by any seasonal and cyclical factors during the current quarter and financial year-to-date under review.

**A5. Unusual items affecting assets, liabilities, equity, net income or cash flows**

There were no unusual items affecting assets, liabilities, equity, net income or cash flows of the Group for the current quarter and financial year-to-date under review.

**A6. Changes in estimates**

There were no changes in estimates that have a material effect in the current quarter and financial year-to-date under review.

**A7. Debt and equity securities**

On 18 January 2021, the shareholders of the Company approved the issuance of up to 80,344,000 free warrants on the basis of 2 warrants for every 5 existing ordinary shares held by the shareholders of the Company whose names appear in the Record of Depositors of the Company on the entitlement date. Thereafter, a total of 80,343,987 new warrants of the

Company were issued and allotted to the entitled shareholders of the Company on 4 February 2021. On 10 February 2021, the Company announced that the issuance of 80,343,987 free warrants have been completed following the listing and quotation of the warrants on the Main Market of Bursa Malaysia Securities Berhad. As at 31 December 2021, none of the warrants have been exercised.

Save for the above, there were no other issuance, cancellation, repurchase, resale or repayment of debt and equity securities for the current quarter and financial year-to-date under review.

**A8. Dividend**

There was no dividend paid during the current quarter under review.

An interim single tier dividend of 1.0 sen per ordinary share amounting to RM2.01 million in respect of the financial year ended 31 December 2020 was paid on 15 July 2021 and had been accounted for in equity as an appropriation of retained earnings in the financial year ended 31 December 2021.

**A9. Segmental information**

The Group's operating segments are animal health products and equipment, food ingredients and others. These operating segments are required to be organised and managed separately according to the nature of products and services as well as specific expertise which require different business and marketing strategies. The segmental results are as follows:

	Individual quarter		Cumulative quarter	
	Current year quarter 31/12/2021 RM'000	Preceding year quarter 31/12/2020 RM'000	Current year- to-date 31/12/2021 RM'000	Preceding year-to-date 31/12/2020 RM'000
<b>Revenue</b>				
Animal health products and equipment	38,406	33,676	133,816	113,838
Food ingredients	7,684	7,518	27,242	30,062
Others	3,006	811	8,447	2,783
	<u>49,096</u>	<u>42,005</u>	<u>169,505</u>	<u>146,683</u>
<b>Profit before tax</b>				
Animal health products and equipment	4,461	3,427	13,694	9,317
Food ingredients	1,338	785	3,221	2,169
Others	(208)	280	690	51
	<u>5,591</u>	<u>4,492</u>	<u>17,605</u>	<u>11,537</u>

**A10. Property, plant and equipment****(i) Acquisitions and disposals**

There were no material acquisitions and disposals during the current quarter and financial year-to-date under review.

(ii) Impairment losses

There were no material impairment losses during the current quarter and financial year-to-date under review.

(iii) Valuation

The Group has not carried out any valuation on its property, plant and equipment during the current quarter and financial year-to-date under review.

**A11. Material events subsequent to the end of the quarter**

On 8 February 2022, Public Investment Bank Berhad (“PIVB”) had on behalf of the Board of Directors of the Company, announced that the Company proposes to undertake a proposed private placement of up to 28,120,300 new ordinary shares in the Company (“Placement Shares”), representing up to 10% of the enlarged number of issued shares in the Company at an issue price to be determined and announced later (“Proposed Private Placement”).

On 9 February 2022, PIVB had on behalf of the Company, submitted the listing application in relation to the Proposed Private Placement to Bursa Malaysia Securities Berhad (“Bursa Securities”).

On 14 February 2022, Bursa Securities had, via its letter, approved the listing and quotation of up to 28,120,300 Placement Shares to be issued pursuant to the Proposed Private Placement, subject to the fulfilment of certain conditions.

Save for the above, there were no material events subsequent to the end of the current quarter that have not been reflected in this interim financial report.

**A12. Changes in the composition of the Group**

On 1 November 2021, the Company completed an internal restructuring exercise involving the transfer of its shares in the following subsidiaries to A2 Fresh Sdn Bhd (“A2F”), via a share swap:

- (i) 1,225,000 ordinary shares in One Lazuli Sdn Bhd (“OLSB”), representing 49% equity interest in OLSB;
- (ii) 588,000 ordinary shares in Nor Lazuli Nutrition (“NLN”), representing 49% equity interest in NLN; and
- (iii) 2,610,818 ordinary shares in Nor Livestock Farm Sdn Bhd (“NLF”), representing 49% equity interest in NLF.

Upon completion of the internal restructuring exercise, A2F became a 49% owned subsidiary of the Company whereas OLSB, NLN and NLF became wholly owned subsidiaries of A2F.

Save for the above, there were no changes in the composition of the Group during the current quarter and financial year-to-date under review.

**A13. Contingent liabilities and contingent assets**

There were no contingent liabilities or contingent assets as at the date of this report.

**A14. Capital commitments**

The capital commitments of the Group as at the end of the quarter under review were as follows:

	<b>RM'000</b>
Approved and contracted for:	
- Construction of GMP-compliant plant in Nilai, Negeri Sembilan	2,697
- Machineries and equipment	1,110
	<u>3,807</u>

**A15. Significant related party transactions**

The related party transactions during the current quarter and financial year-to-date under review are as follows:

	<b>Individual quarter</b>		<b>Cumulative quarter</b>	
	<b>Current year quarter 31/12/2021 RM'000</b>	<b>Preceding year quarter 31/12/2020 RM'000</b>	<b>Current year-to-date 31/12/2021 RM'000</b>	<b>Preceding year-to-date 31/12/2020 RM'000</b>
NLF purchases feed from NLN	99	128	785	306
NLF purchases milk replacer from NLN	2	9	11	13
NLN purchases hay from NLF	3	10	33	23
OLSB purchases feed from NLN	-	1	20	6
OLSB provides transportation services to NLN	2	4	14	11
NLF purchases anti-inflammatory medication, mastitis medication, antibiotics, anti-parasitics and dairy milk machine parts from OLSB	7	16	124	39
NLF purchases milking machines from OLSB	-	-	-	167
NLN rents an office space from OLSB	1	3	10	6
NLF rents an office space from OLSB	-	-	2	1
NLF rents a farm land from Raja Mariam Binti Raja Rustam Shahrome and Dr Mai Lam @ Rosli Mai Lam	8	7	30	15

	<b>Individual quarter</b>		<b>Cumulative quarter</b>	
	<b>Current year quarter 31/12/2021 RM'000</b>	<b>Preceding year quarter 31/12/2020 RM'000</b>	<b>Current year-to-date 31/12/2021 RM'000</b>	<b>Preceding year-to-date 31/12/2020 RM'000</b>
NLN rents a factory building from Raja Mariam Binti Raja Rustam Shahrome and Dr Mai Lam @ Rosli Mai Lam	8	7	30	15
OLSB rents an office space from Raja Mariam Binti Raja Rustam Shahrome	45	45	180	90

**B. ADDITIONAL INFORMATION REQUIRED BY THE MAIN MARKET LISTING REQUIREMENTS OF BURSA MALAYSIA SECURITIES BERHAD**

**B1. Review of performance**

The Group recorded revenue of approximately RM49.10 million for the current quarter, an increase of approximately RM7.09 million compared to the revenue of approximately RM42.01 million in the preceding year's corresponding quarter. Revenue from animal health products and equipment increased by approximately RM4.73 million from approximately RM33.68 million in the preceding year's corresponding quarter to approximately RM38.41 million in the current quarter. Revenue from food ingredients increased by approximately RM0.16 million from approximately RM7.52 million in the preceding year's corresponding quarter to approximately RM7.68 million in the current quarter. Revenue from the dairy business which is categorised under others segment, increased by approximately RM1.47 million from approximately RM0.24 million in the preceding year's corresponding quarter to approximately RM1.71 million in the current quarter.

In line with the increase in revenue, the Group's profit before tax for the current quarter of approximately RM5.59 million was approximately RM1.10 million higher compared to the profit before tax of approximately RM4.49 million reported for the preceding year's corresponding quarter.

For the financial year under review, the Group recorded revenue of approximately RM169.51 million, an increase of approximately RM22.83 million compared to the revenue of approximately RM146.68 million in the preceding year. Revenue from animal health products and equipment increased by approximately RM19.98 million from approximately RM113.84 million in the preceding year to approximately RM133.82 million in the current year with approximately RM9.89 million being contributed by OLSB and NLN during the first half of 2021. Revenue from food ingredients decreased by approximately RM2.82 million from approximately RM30.06 million in the preceding year to approximately RM27.24 million in the current year, but the decrease was mitigated by an increase in revenue from the dairy business which is categorised under others segment, of approximately RM4.19 million from approximately RM0.37 million in the preceding year to approximately RM4.56 million in the current year.

Consistent with the increase in revenue, the Group's profit before tax for the financial year under review of approximately RM17.61 million was approximately RM6.07 million higher compared to the profit before tax of approximately RM11.54 million reported for the preceding year.

**B2. Material changes in the quarterly results compared to the immediate preceding quarter**

The Group's revenue of approximately RM49.10 million for the current quarter was approximately RM5.26 million higher compared to the revenue of approximately RM43.84 million reported for the preceding quarter. Revenue from animal health products and equipment increased by approximately RM3.81 million from approximately RM34.60 million in the preceding quarter to approximately RM38.41 million in the current quarter. Revenue from food ingredients increased by approximately RM0.09 million from approximately RM7.59 million in the preceding quarter to approximately RM7.68 million in the current quarter.

In line with the increase in revenue, the Group's profit before tax for the current quarter of approximately RM5.59 million was approximately RM0.75 million higher compared to the profit before tax of approximately RM4.84 million reported for the preceding quarter.

**B3. Prospects**

The continued expansion of our capacity and operations through our future plans would provide a platform to grow and sustain our business. The Group will continue to focus on strengthening its production capabilities, product competitiveness and market position, while constantly seeking ways to mitigate the risks associated with its business. The Group will also continue to improve its internal controls and processes based on prudent management practices. In addition to improving on current operations, the Group is vigilant in identifying new business opportunities that has the potential for continuous growth and expansion.

In line with the projected growth of the Malaysian economy, the livestock industry is also anticipated to grow due to the corresponding growing Malaysian population resulting in the demand for meat as a source of protein to soar. The estimated increase in livestock in Malaysia is expected to result in correlating increase in demand for animal pharmaceutical and veterinary products, including animal feed to meet the rising needs. This is expected to augur well for the Group to ride on the growth trajectory in line with the government's endeavour to develop a sustainable livestock industry in the country for national food security. We are also anticipating growth in our dairy production business segment due to the projected uptrend in the local market. The production of milk in Malaysia was expected to increase in line with the government's aim to increase the country's fresh milk self-sufficiency level to 100% within five years and this will create abundant opportunities for the Group to capitalise on.

The Covid-19 pandemic that has been sweeping the globe in recent times has been anticipated to have a negative impact on the Malaysian macro-economy as well as on the economic welfare of its population. Notwithstanding these developments, the Group which is actively involved in the animal health and nutrition market, is within the ambit of the food industry's supply chain and the Board is cautiously optimistic of the minimal impact that the pandemic will have on our operations.

**B4. Profit forecast**

The Group has not issued any profit forecast in any form of public documentation and announcement.

**B5. Tax expense**

	Individual quarter		Cumulative quarter	
	Current year quarter 31/12/2021 RM'000	Preceding year quarter 31/12/2020 RM'000	Current year-to-date 31/12/2021 RM'000	Preceding year-to-date 31/12/2020 RM'000
<b>Current tax</b>				
Current year	732	1,116	3,670	3,066
(Over)/under provision in prior years	(135)	22	(66)	22
	<u>597</u>	<u>1,138</u>	<u>3,604</u>	<u>3,088</u>
<b>Deferred tax</b>				
Origination of temporary differences	1,426	19	1,426	19
Under provision in prior years	56	64	56	64
	<u>1,482</u>	<u>83</u>	<u>1,482</u>	<u>83</u>
	<u>2,079</u>	<u>1,221</u>	<u>5,086</u>	<u>3,171</u>

The effective tax rates of the Group for the current quarter and financial year-to-date of 37.18% and 28.89% respectively were higher than the statutory tax rate of 24.00% as certain subsidiaries were in loss making positions and that certain expenses were not allowable for tax purposes.

**B6. Notes to the Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income**

	Individual quarter		Cumulative quarter	
	Current year quarter	Preceding year quarter	Current year-to-date	Preceding year-to-date
	31/12/2021 RM'000	31/12/2020 RM'000	31/12/2021 RM'000	31/12/2020 RM'000
<b>Profit before tax is arrived at after charging / (crediting):</b>				
Depreciation	1,191	991	3,607	2,166
Inventories written off	285	590	809	2,172
Inventories written down/(back)	341	(831)	590	(279)
(Write back)/impairment losses on trade receivables	(102)	(558)	258	(318)
Fair value changes on other investment	6	1	7	9
Interest expense	253	297	1,278	1,382
Loss on disposal of biological assets	14	-	161	-
Fair value changes on biological assets	(137)	(461)	(560)	(466)
Interest income	(42)	(33)	(175)	(177)
(Gain)/loss on foreign currency exchange	(290)	335	516	954

Save for the above, the other items as required under Appendix 9B Part A (16) of the Main Market Listing Requirements of Bursa Malaysia Securities Berhad are not applicable.

**B7. Status of corporate proposals**

There is no corporate proposal announced but not completed as at the date of this report.

**B8. Other investment**

	As at 31/12/2021 RM'000	As at 31/12/2020 RM'000
<b>Financial asset at fair value through profit or loss</b>		
Quoted shares in Malaysia	50	50
Less: Impairment loss	(26)	(19)
	<u>24</u>	<u>31</u>

**B9. Borrowings**

	<b>As at 31/12/2021 RM'000</b>	<b>As at 31/12/2020 RM'000</b>
<b>Non-current liabilities (secured)</b>		
Term loans	<u>25,698</u>	<u>30,429</u>
<b>Current liabilities (secured)</b>		
Term loans	<u>4,579</u>	<u>4,369</u>
<b>Total borrowings</b>	<u><u>30,277</u></u>	<u><u>34,798</u></u>

All borrowings are denominated in Ringgit Malaysia.

**B10. Material litigation**

There was no litigation which has a material effect on the financial position of the Group and the Board was not aware of any proceedings pending or of any fact likely to give rise to any proceedings as at the date of this report.

**B11. Dividend**

On 24 December 2021, the Board of Directors declared an interim single tier dividend of 1.0 sen per ordinary share totalling RM2.01 million in respect of the financial year ended 31 December 2021, which had been paid on 25 January 2022 to shareholders registered at the close of business on 13 January 2022. The dividend had been accounted for in equity as an appropriation of retained earnings in the financial year ended 31 December 2021.

**B12. Derivative financial instruments**

The Group does not have any derivative financial instruments as at the end of the current quarter.

**B13. Gains/losses arising from fair value changes of financial liabilities**

There were no material gains or losses arising from fair value changes of financial liabilities during the current quarter and financial year-to-date under review.

**B14. Earnings per share**

	Individual quarter		Cumulative quarter	
	Current year quarter	Preceding year quarter	Current year-to-date	Preceding year-to-date
	31/12/2021	31/12/2020	31/12/2021	31/12/2020
Profit attributable to owners of the parent (RM'000)	3,137	2,634	11,268	7,285
Weighted average number of ordinary shares in issue ('000)	200,860	200,860	200,860	195,087
Shares under warrant deemed to have been issued for no consideration ('000)	80,344	-	80,344	-
Weighted average number of ordinary shares for computing diluted earnings per share ('000)	281,204	200,860	281,204	195,087
Earnings per share				
- Basic (sen)	1.56	1.31	5.61	3.73
- Diluted (sen)	1.12	1.31	4.01	3.73

**B15. Net assets per share**

Net assets per share attributable to owners of the parent is arrived at by dividing the total equity attributable to owners of the parent at the end of the financial period by the number of ordinary shares in issue at the end of the financial period.

	As at 31/12/2021	As at 31/12/2020
Total equity attributable to owners of the parent (RM'000)	133,373	124,114
Number of ordinary shares in issue ('000)	200,860	200,860
Net assets per share attributable to owners of the parent (RM)	0.66	0.62

**B16. Reorganisation debit balance**

The reorganisation debit balance arose from the acquisition of RMM on 28 September 2016 based on the difference between the share capital issued by the Company and the share capital issued by RMM amounting to approximately RM59.49 million.